SHINE Technologies announced recently that it will supply ImaginAb Inc., a global biotechnology company focused on developing immuno-oncology imaging agents and therapeutic radiopharmaceuticals, with lutetium-177 (Lu-177) to support the company’s preclinical and clinical needs.

“We are thrilled to continue to partner with leading biotechnology companies like ImaginAb in the mission to drive innovation of cancer therapeutics,” SHINE CEO Greg Piefer said in a statement. “We are proud to deliver Lu-177 and other medical isotopes as they play a major role for biotechnology companies like ImaginAb to continue to innovate treatment solutions for critically ill patients.”

According to a release, SHINE will begin supplying ImaginAb immediately for the company’s development activities and for therapeutic clinical trials planned for 2023.

ImaginAb is developing radiopharmaceutical therapy agents based on proprietary minibody and cys-diabody platform technologies.

Financial terms of the agreement were not released.